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his latest edition of Neurotransmitter represents another step forward in our effort to
communicate the progress taking place among the clinical partners at the George
Washington University (GW). Inside these pages, we illuminate the rich tapestry of
the neurosciences and the broad expertise of the GW Institute for Neuroscience
(GWIN) and the GW University Hospital Neurological Institute.
This third magazine deals with subjects that overwhelm daily headlines. Douglas Nixon, M.D., Ph.D., chair of the Department of Microbiology, Immunology, and
Tropical Medicine and Walter G. Ross Professor of Basic Science Research at GW’s
School of Medicine and Health Sciences (SMHS), leads a group of investigators from
across the University who are exploring how the Zika virus may produce devastating abnormalities in brain development and identifying other likely areas of nervous system infection. Neurotransmitter also discusses the psychiatric ramifications
of the global refugee crisis.
We are excited to announce a major recruitment to GW. Kevin Pelphrey, Ph.D., a
world-renowned investigator on autism, will lead the GW Autism and Neurodevelopmental Disorders Institute. Pelphery will build collaborations across several GW
colleges, including SMHS, the Columbian College of Arts and Sciences, and the
Milken Institute School of Public Health, as well as with clinical partners the GW Hospital, the GW Medical Faculty Associates, and Children’s National Health System.
Collaborations are key to excellence in science and medicine. The Joint Commission recently acknowledged our collective efforts by designating GW Hospital
as a comprehensive stroke center. The commission noted how well the GW Hospital
administration, staff, and physicians worked together to provide advanced stroke
care. We offer a personal account of the impact modern stroke care has had on
one of our patients. In addition to this success story, we provide an update on the
groundbreaking research of Mohamad Koubeissi, M.D., and Donald Shields, M.D.,
Ph.D., FACS, in dramatically reducing the frequency of seizures among patients with
epilepsy.
Beyond the research conducted at GW, we feature pieces on scientists who
visited us to present their work. At GWIN’s 6th Annual Neuroscience Symposium,
investigators from across the country presented discoveries in multiple sclerosis
and Alzheimer’s disease. GW also welcomed back former psychiatry resident Brandon Kohrt, M.D., Ph.D., RESD ’13, who gave the prestigious Seymour Perlin, M.D.,
lecture.
We hope you enjoy this edition of Neurotransmitter.
Please go to smhs.gwu.edu/neurotransmitter to view or share a copy of this or
previous editions of Neurotransmitter.
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and education, under unified leadership to optimize the health of our patients now and into the future through a multidisciplinary
approach, state-of-the-art technology, and innovative treatment trials. To learn more, visit www.gwhospital.com/hospital-services/theneurosciences-institute-at-the-george-washington-university-hospital.
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THE NEURO-IMMUNE INTERFACE:
GLIA, NEURONS, AND DISEASE
Stephen Hauser,
M.D., found in
his research that
antibodies targeting
cells that promote
antibody production
reduced disease
activity within weeks
of treatment. “This
discovery … enabled
a paradigm shift in

Neuro-immune diseases — particularly Alzheimer’s, multiple sclerosis (MS), and myasthenia gravis (MG) — took center stage at the 6th Annual Neuroscience Symposium, a
day-long event sponsored by the GW Institute for Neuroscience. “The Neuro-Immune
Interface: Glia, Neurons, and Disease”-themed symposium featured two keynote speakers, as well as presenters from the GW School of Medicine and Health Sciences (SMHS)
and Children’s National Health System (Children’s National).
“This [symposium] is a wonderful thing to do,” said keynote speaker Carla Shatz,
Ph.D., Sapp Family Provostial Professor, David Starr Jordan Director of Stanford Bio-X,
and professor of biology and neurobiology at Stanford University.
Shatz, in “Saving the Synapse: Developmental Critical Periods and Alzheimer’s Disease,” asserted that if researchers could better understand the cellular and molecular mechanisms underlying developmentally critical periods, then they could use the
mechanisms in the adult brain to help repair injuries in stroke and Alzheimer’s patients.
The second keynote speaker, Stephen L. Hauser, M.D., Robert A. Fishman Distinguished Professor and chair of the Department of Neurology at the University of California – San Francisco, focused on MS.
Hauser, whose research targeted B cell-based therapies and their impact on the disease, found that antibodies targeting cells that promote antibody production reduced

understanding how
the inflammatory
phase of MS
develops.”

LINDA KUSNER, Ph.D.

STEPHEN L. HAUSER, M.D.

CARLA SHATZ, Ph.D.

disease activity within weeks of treatment. “This discovery … enabled a paradigm shift
in understanding how the inflammatory phase of MS develops,” he said.
Robert Miller, Ph.D., senior associate dean for research and Vivian Gill Distinguished
Research Professor at SMHS, who presented “Cellular Interactions Regulating CNS Myelination, Demyelination, and Early Myelin Repair in Vertebrate CNS,” also focused on
MS, namely the role of astrocytes, or star-shaped glial cells in the brain and spinal cord,
in myelination, the creation of the fatty insulation protecting nerves.
In addition to the research on Alzheimer’s and MS, Linda Kusner, Ph.D., associate research professor of pharmacology and physiology at SMHS, discussed MG, a rare and
debilitating autoimmune disorder that causes muscle weakness. Through her work,
Kusner discovered that the expression of the protein survivin could be part of a mechanism that keeps cancer cells alive, thereby linking cancer and autoimmune disease in
MG and other autoimmune disorders.
This year’s symposium also included discussions from SMHS Ph.D. candidates and
postdoctoral fellows as well as poster presentations from SMHS and Children’s National researchers.

Through her research, Linda Kusner, Ph.D., discovered that the expression of the protein
survivin keeps cancer cells alive, thereby linking cancer and autoimmune disease.
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SPANNING THE SPECTRUM OF AUTISM

KEVIN PELPHREY, Ph.D.
Director of the Autism
and Neurodevelopmental
Disorders Institute and
professor of pharmacology
and physiology at the
GW School of Medicine
and Health Sciences

The George Washington University’s research portfolio has recently begun to expand
thanks to the expertise of Kevin Pelphrey, Ph.D., new director of the Autism and Neurodevelopmental Disorders Institute (ANDI) and professor of pharmacology and physiology at the GW School of Medicine and Health Sciences.
Pelphrey will connect the University’s full research spectrum, including faculty members representing six GW colleges, with clinical partners GW Hospital, Children’s National Health System, and the GW Medical Faculty Associates. The goal is to create a onestop resource for families affected by autism in the Washington, D.C. metropolitan area.
Pelphrey, who is the parent of a child with autism, has more than 15 years of experience in autism and neuroscience research. He specializes in cognitive neuroscience
and developmental disorders and currently holds seven active grants, including a $15
million National Institutes of Health grant from the Autism Centers of Excellence Program. Pelphrey will also be the first to hold the endowed title of the Carbonell Family
Professor in Autism and Neurodevelopment Disorders.
At ANDI, which received $5 million from GW and will be located on the University’s
Virginia Science and Technology Campus in Ashburn, Virginia, Pelphrey and his team
will focus on adults with autism and women with autism.

TAKING AIM AT NEW TARGETS FOR
MYASTHENIA GRAVIS TREATMENT

THYMECTOMIES AND
MYASTHENIA GRAIVS

Linda Kusner, Ph.D., associate research professor in the department of pharmacology
and physiology at the GW School of Medicine
and Health Sciences, received a multi-year
Muscular Dystrophy Association research
grant totaling nearly $300,000 to provide a
new fundamental understanding of the basic
IN MYASTHENIA GRAVIS
mechanisms of autoimmunity and validating a
the immune system makes
new therapeutic target for myasthenia gravis
antibodies that damage or
(MG).
block many of the muscle’s
Kusner aims to develop a therapy for MG
acetylcholine receptors on
that might eliminate or lessen the need for
the surface of muscle cells,
corticosteroids, the current standard of care.
preventing the chemical from
With colleagues, she has discovered a probinding to the damaged
tein called survivin present in MG-affected
receptors and reducing
cells that the group believes supports the
muscle contractions, leading
presence of autoreactive immune cells by alto weakness and fatigue.
lowing them to escape cell death. In studies
that targeted the protein, Kusner and her team observed a reduction in the
levels of antibodies in the MG disease process.
In her new work, Kusner will analyze thymus tissue from MG patients as well
as from healthy individuals to determine whether the survivin protein is present in both instances. Kusner’s team also will evaluate survivin-based therapeutics in an MG rodent model to assess the therapeutics’ ability to improve
observable weakness, decrease the expression of autoreactive immune cells,
decrease acetylcholine receptor-specific antibodies, and decrease damage
to the nerve-muscle junction.

Henry Kaminski, M.D., chair of the Department of Neurology and Meta Amalia Neumann Professor of Neurology at
the GW School of Medicine and Health
Sciences, has found that removing the
thymus effectively reduced patients’
muscle weakness, as well as the need
for immunosuppressive drugs and hospitalizations.
“While surgery is expensive and not
without risk, this research will empower patients and their doctors to make
informed decisions regarding treatment,” said Kaminski.
Previous studies have suggested
that removing the thymus may reduce MG symptoms — droopy eyelids;
blurred or doubled vision; difficulty
talking, breathing, and swallowing;
and neck and limb movement problems — but Kaminksi’s study, published
in the New England Journal of Medicine, is the first randomized study of
thymectomy in MG patients, providing
clinical evidence of the benefits of the
surgery.
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Beyond the Buzz
GW RESEARCHERS JOIN INTERNATIONAL ACTION ON THE ZIKA VIRUS

BY C.J. TRENT-GURBUZ
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T

he countdown at the University of Wisconsin-Madison (UW) began on March 7, 2016,
when researcher David O’Connor, Ph.D.,
professor in the Department of Pathology
and Laboratory Medicine at the School of
Medicine and Public Health at UW, and his
team infected a pregnant rhesus macaque monkey with the
Zika virus.
“They’re releasing all of the results from her pregnancy,
live,” says Chiara Manzini, Ph.D., assistant professor of pharmacology and physiology at the GW School of Medicine and
Health Sciences (SMHS). “They’re planning to do a C-section
as soon as she’s ready because they want to get the placenta
[to analyze it].”
The free flow of data from UW is standard — now — for Zika
virus research. While in the past, investigators might have
worked in siloed environments, the Zika virus has spurred researchers around the globe to share data as soon as possible.
“This is a race,” Manzini says.
In the months since the World Health Organization declared the Zika virus an international public health emergency, researchers have made significant strides; specifically,
they’ve connected the virus to neurological disorders and
established public health protocols for those living in, or visiting, the Zika zone.
“Research has not only
MAKING STRIDES
added to the body of evidence
In the months since the World
suggesting that Zika virus does
Health Organization declared
cause microcephaly, but there
the Zika virus an international
are also additional suggespublic health emergency, retions that neurological damsearchers have connected the
age in infants born to mothers
virus to neurological disorders
and established public health
who have become infected
protocols for those living in,
with Zika during pregnancy is
or visiting, the Zika zone.
worse than we thought,” explains Douglas Nixon, M.D.,
Ph.D., chair of the Department
of Microbiology, Immunology, and Tropical Medicine and
Walter G. Ross Professor of Basic Science Research at SMHS.
“There may be a number of different neurological problems
in addition to microcephaly that infants may develop.”
Or, as Manzini phrases it: “Microcephaly is just the tip of
the iceberg.”
The virus, she explains, infects the brain and kills the
proliferating cells, which can cause severe growth defects
in the developing fetal brain. Microcephaly, a condition
in which a baby is born with an abnormally small head and
potential brain damage, is one possible result, as is GuillainBarré Syndrome, a rare autoimmune disorder of the central
nervous system.
It’s precisely because the virus has been linked to these
disorders that researchers are sharing data as they sprint toward a solution.

“Microcephaly is just the
tip of the iceberg.”
CHIARA MANZINI, Ph.D.

“Nobody has the general expertise to deal with this; it isn’t
like other epidemics where it’s simply the passing of the virus
and it just infects the host,” says Jeffrey Bethony, Ph.D., professor of microbiology, immunology, and tropical medicine
at SMHS. “[Zika] has long-term effects that you wouldn’t even
know existed unless you had a multidisciplinary team.”
That team includes people like himself, a vaccinologist,
and those such as Manzini, who studies brain malformations,
as well as neurologists and fetal immunologists. For her part,
Manzini is using a zebrafish model to look at “brain development in real time on a very short timeline.” Researchers have
also looked at other animal models — the rhesus macaque at
UW, mice, and fruitflies — and while none are precisely perfect
for Zika, all offer some type of information, Manzini says, adding to the communal pool of data.
The National Institutes of Health (NIH) is also working to
develop a vaccine as soon as possible, though that comes
with certain challenges, according to Nixon and Bethony.
The NIH has to ensure the vaccine isn’t more harmful than the
virus; in other words, it has to be safe. It’s a process that requires significant testing despite the urgency.
“Who do you want to vaccinate?” Bethony asks. “You want to
vaccinate women of childbearing years, or potential mothers.”
Developing a vaccine for such a patient group is particularly difficult, he says, adding “the idea of a physician is ‘do no
harm,’ so they’re going to be very cautious.”
Right now, according to the NIH, its National Institute of
Allergy and Infectious Diseases (NIAID) is focusing on a DNAbased vaccine similar to the West Nile Virus vaccine. Researchers also are exploring a live-attenuated, or weakened, vaccine
that’s related to the vaccine for dengue virus, which is a member of the Flavivirus genus, like Zika, yellow fever, and chikungunya. NIAID is looking at other potential vaccine approaches
as well, including a whole-particle inactivated vaccine similar
to that used against dengue and Japanese Encephalitis.
“In terms of physically making a vaccine that could be tested
in people, I think we’re getting close — quite soon,” says Nixon.
Meanwhile, at GW, those interested in Zika-related research are applying for grants, and a Zika interest group, Nixon says, has formed between those at SMHS, the GW Milken
Institute School of Public Health, and GW clinical partners,
the GW Medical Faculty Associates and Children’s National
Health System.
“People are becoming excited about Zika research,” he
says, “and it really is a very exciting opportunity.”
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Studying Clues to Fetal Mysteries
GW RESEARCHER EXPLORES NEURAL DEVELOPMENT FROM ITS EARLIEST STAGE

Y
“My fundamental
hypothesis is
development
in circuits are
specialized, and it’s
a specifically tuned
system at work
to do something
different than
the adult brain.”
MATTHEW COLONNESE, Ph.D.
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BY THOMAS KOHOUT AND ERIC BUTTERMAN

ou see it all the time, couples placing headphones on a pregnant woman’s belly to share
a little Bach or Beatles with their soon-to-be newborn, reading the stories they imagine
one day telling just before bedtime, or stomaching all manner of juice concoctions in an
effort to strike that ideal nutritional balance. It’s all done in the name of development. In
the anxious months leading up to the birth of a child, expectant parents will try just about
anything to give their growing baby a little edge.
But what’s really going on during pregnancy? How
WHAT’S GOING ON?
aware is that fetus growing inside? What can science do
Knowing how aware a fetus is
in the womb may allow for recto ensure the best possible outcome after birth? Despite
ognition of problems with the
all that medical professionals have come to know about
fetus earlier, which, combined
pregnancy, neural development remains more enigmatic
with treatment, might just alter
than indubitable. Unravelling the complex wiring processquality of life concerning issues
es taking place within the developing brain may allow for
such as preterm infancy.
early recognition of neurological problems affecting life
after birth.
With the support of a nearly $2 million grant in 2013 from the National Eye Institute,
Matthew Colonnese, Ph.D., assistant professor of pharmacology and physiology at the
GW School of Medicine and Health Sciences (SMHS) and a researcher with the George
Washington University Institute for Neuroscience, is working to shed more light on the
fetal brain developmental period in the hopes of providing those answers.

Eyeing Development
Colonnese has been exploring the subject of fetal brain development for years, dating
back to his days as a graduate student. “At Yale, I was studying how the retina lines up to
targets centrally. We knew this required activity in these targets, but had little idea what
this activity consisted of.” Exploring how the brain constructs the neural circuitry that links
the retina to the thalamus and the cerebral cortex, Colonnese says, ultimately led him to
the work he delves in today.
Colonnese wanted to understand the timeline in brain development when the various
pieces of the brain begin to talk to one another. Before arriving at GW, he collaborated
with a team of clinicians in Paris who made brainwave recordings on preterm infants, at
ages before they would have been born — in gestational weeks 28–34. The group also
studied neural activity in the cortex using baby rats.
“We designed an experiment to give those pre-term infants light flashes and did the
same with the rats,” explains Colonnese, who heads SMHS’s Laboratory of Systems Neural
Development. “We could map the activity patterns that were occurring in the babies onto
the rat.”
The work established a baseline for comparison between the fetal rat brain and the human fetus. By matching brainwave patterns, and understanding what patterns to expect
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“What’s most interesting to me are spending days sticking electrodes in and having no
idea what you will see. It’s completely unknown — it feels like exploring the moon.”
MATTHEW COLONNESE, Ph.D.

at the equivalent ages, researchers could extrapolate observations in the rat and mouse models onto the fetal brain
development timeline.

Measuring the Flow
In his investigations, Colonnese has noted that many of the
neural circuits in the fetal brain are specialized and specifically tuned to complete a developmental task that is different than the task they perform in the adult brain. Colonnese
wondered whether the specialized properties of the fetal
neurocircuitry might prevent the normal flow of information
from the eye to the brain.
Using an array of electrodes to simultaneously record the
activity of hundreds of neurons across multiple regions of
the brain, the team discovered that the thalamus, acting as
a way station for signals traveling between the eye and the
cortex, contains a “booster” that amplifies the signals before
sending them to the rest of the brain. Those observations
were published in the October edition of eLife.
Typically in the adult brain, the eye sends information in
a specific pattern, explains Colonnese. The eye transmits a
refined stream of signals. “In the adult brain, it’s graded,” he
says. “If you see a little bit of light, you get a little response; if
you see a lot of light, you get a big response.”
In the fetal brain, on the other hand, the eye doesn’t provide that same pattern. Instead, the retina sends a massive
burst of activity that Colonnese believes reflects a unique
circuitry there to amplify the activity early in fetal development. “In the fetal brain, you get nothing, nothing, nothing,
BOOM! You get everything.
“You can’t see using that information,” he adds. “It’s a just
massive burst of stuff that is going through telling the other
parts of the brain, ‘yes something happened.’ ”
Colonnese believes this booster mechanism has evolved
to help maintain signal strength between the various parts
of the brain while the circuitry is being established. The amplifier, he says, explains how the fetal brain continues to stay
active despite underdeveloped synapses.
The next goal, Colonnese says, will be to generate a kind
of EEG “atlas” of neurodevelopment, pinpointing when the
fetal brain transitions from a developmental stage to more
adult-like patterns of behavior. With that information at their
disposal, he says, physicians could identify problems with
particular brain regions through disruptions in brain activity.
“This may give neonatologists a sense of what is wrong
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MATTHEW COLONNESE, Ph.D.

with a child who has an abnormal EEG,” he says, and point to
a possible plan to address those problems.

The Search is Just Starting
Despite early strides, the major challenge will continue to
be understanding the large number of changes during the
brain’s development. Colonnese explains that trying to link
a specific pattern change to a specific circuit can be similar
to searching for a needle in a haystack.
“Everything is changing. How do you separate one
change among the many we are observing?” he asks. “Our
approach is to systematically go through the many potential
candidate cells, neurotransmitters, and receptors and remove them, one by one, to see which can modify the timing
of development.”
Colonnese knows there is a long way to go in his work, but
the days with little to go on are worth it for the ones that reveal breakthroughs. “You think about the brainwave patterns
in the fetus that have been described for something like 50
years, but their origin has always been mysterious,” he says.
“What’s most interesting to me are spending days sticking
electrodes in and having no idea what you will see. It’s completely unknown — it feels like exploring the moon — and it’s
even trying to answer the most basic question: ‘Why is the
fetus kicking?’ You don’t have to be a researcher to ask that
one. But hopefully this work will be a part of answering it.”

The Stimulation Inspiration
TRACKING THE RESULTS OF LOW-FREQUENCY DEEP BRAIN STIMULATION ON EPILEPSY PATIENTS
BY C.J. TRENT-GURBUZ

W

hen the National Geographic
cameras began rolling last year,
Danette Cunningham was struggling with epilepsy: she had
twice suffered from seizures
while driving and had experienced constant shakiness. Cunningham’s seizures originated from both hippocampi;
for her, surgery would not be an option, and medications had already
proven ineffective. Mohamad
Koubeissi, M.D., director of the
Epilepsy Center and associate
professor of neurology at the
GW School of Medicine and
Health Sciences (SMHS), however, had a potential solution.
As documented in the
TV show “Breakthroughs,”
Koubeissi
used
a
pioneering approach to treat

“In previous deep brain
stimulation trials, the results
have never been that good.”
MOHAMAD KOUBEISSI, M.D.

Cunningham and a second patient, Yakov Krug,
both of whom were diagnosed with temporal lobe epilepsy. Koubeissi, and a GW Hospital surgical team led by
Donald Shields, M.D., Ph.D., FACS, assistant professor of
neurological surgery, implanted a permanent electrode
for Deep Brain Stimulation 5 inches inside the brains of

Cunningham and Krug. The stimulator sent out low frequency electrical pulses into the hippocampus.
“All previous trials used high frequencies in the range
of 90 to 130 pulses per second, or hertz; that’s very high,”
Koubeissi explains. “In the current trial, what we’re using
is 1 to 5 hertz, so it’s low frequencies, which explains why
the patient doesn’t feel anything. Over time,
this stimulation tends to alter the seizure
network or create changes within the
seizure network that paves the road
to fewer seizures and maintains
or even improves cognitive
function.”
A month after healing,
Cunningham and Krug each
showed a massive reduction
in their seizures.
“In previous deep brain
stimulation trials, the results
have never been that good,”
Koubeissi says. “There are
numerous other targets in the
brain that have been tried, and,
in the best of subjects, seizures decrease by 30 percent or 40 percent, and
some patients do not seem to benefit at all.
Despite the small sample in our study, the benefit is
more than 90 percent.”
A year has since passed, and the results, though limited to two patients, “continue to be unique and promise to be a real game changer.” The next step, Koubeissi
says, is identifying more patients who fit the criteria for
the procedure and designing an extensive clinical trial.
He’d also like to apply for funding and, depending on
the efficacy and tolerability of the intervention in a larger
sample, seek FDA approval.
Koubeissi is encouraging any patients who might qualify for the treatment to reach out to the SMHS Department
of Neurology’s research office at raly@mfa.gwu.edu.
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Turn Back Time by Acting Fast
GW HOSPITAL’S STROKE TEAM IS AMONG THE NATION’S LEADERS IN ACUTE CARE

L
TIME IS BRAIN
In the event of a stroke, rapid
response is crucial; quick recognition and treatment can save
lives or minimize the long-term
effects of a stroke. GW Hospital is
certified as a Comprehensive Stroke
Center, which is a designation that
recognizes the specific capabilities
of hospitals that can treat the most
complex stroke cases. Less than
2 percent of U.S. hospitals — less
than 100 — have that certification.

BY STEVE GOLDSTEIN

ast autumn, an ambulance rushed into the emergency entrance of George Washington
University Hospital (GW Hospital) bearing a middle-aged woman who had developed an
acute left-sided weakness that morning. Fearing a stroke, her family called 911. Upon examination, doctors assessed her as an 11 on the National INstitutes of Health (NIH) Stroke
Scale, evidenced by dysarthria (slurred speech), left facial droop, and severe left arm and
leg weakness. An X-ray computed tomography scan (CT) of her head ruled out bleeding
in the brain.
The patient was given IV tPa (intravenous clot-busting medication) less
than an hour after symptom onset. A
CT angiogram of the head showed a
blood clot in the right middle cerebral
artery. She was taken to the angio suite
where neurointerventionalist Wayne
Olan, M.D., assistant professor of neurological surgery, and colleague Dimitri Sigounas, M.D., assistant professor
of neurological surgery, used a stentretriever device to successfully remove
the clot. After the procedure she had
only mild left facial weakness and mild
left hand incoordination. The woman
was recently seen in the GW Medical
Faculty Associates clinic and has subtle
left facial droop but is otherwise back to
normal. She is working, performing all
of her activities of daily living, walking
independently, and driving.
Stroke is a killer. Thanks to new procedures and proactive stroke prevention measures,
stroke has, in the last decade, dropped to fifth from the third leading cause of death in
the United States. Rapid response is crucial; quick recognition and treatment can save
lives or minimize the long-term effects of a stroke. “Time is brain” is a key mantra of stroke
neurology. Not long before the incident described above, GW Hospital was certified as
a Comprehensive Stroke Center, a designation which may have saved the woman’s life.
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“We have the clinical expertise to take care of complicated stroke cases. In addition
to providing the routine care that Primary Stroke Centers can deliver, we can provide
endovascular procedures on a 24/7 basis, and we’re actively engaged in research trials.
It also means we have more vigorous metrics and measures that must be collected.”
CHRISTOPHER LEON-GUERRERO, M.D.

TAKING THE CARE FURTHER
In addition to the routine care that GW delivers as a Comprehensive
Stroke Center, the hospital is also actively engaged in research trials. It
is constantly examining data and re-evaluating its service to patients.
What is a Comprehensive Stroke Center (CSC)? The designation recognizes the specific capabilities of hospitals
that can treat the most complex stroke cases. Less than
2 percent of U.S. hospitals — less than 100 — have that certification. “It means that we have the clinical expertise to take
care of complicated stroke cases,” says Christopher LeonGuerrero, M.D., assistant professor of neurology at the GW
School of Medicine and Health Sciences, who attends the
stroke and general inpatient service at GW Hospital. “In addition to providing the routine care that Primary Stroke Centers can deliver, we can provide endovascular procedures
on a 24/7 basis, and we’re actively engaged in research trials. It also means we have more vigorous metrics and measures that must be collected, so we’re constantly examining
data and re-evaluating service to patients.”
The Joint Commission and American Heart Association/
American Stroke Association instituted a new level of certification in September 2012 to identify the medical facilities with the resources, staff, and training, such as advanced
imaging capabilities and specialized treatments, necessary
for the care of complex stroke cases. “This designation
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demonstrates not only the
SPOTTING SIGNS OF STROKE
unique expertise of our phy>> Sudden numbness or
sicians, but also the exacting
weakness of the face,
collaborative procedures that
arm, or leg, especially
GW Hospital has developed
on one side of the body
involving everyone from the
>> Sudden confusion,
transport staff, technologists,
trouble speaking, or
nurses, and physicians to the
understanding
CEO and hospital leadership,”
says Henry Kaminski, M.D.,
>> Sudden trouble seechair of the Department of
ing or blurred vision
Neurology and Meta Amalia
in one or both eyes
Neumann Professor of Neurol>> Sudden trouble walkogy at SMHS.
ing, dizziness, loss of
GW’s CSC certification is
balance or coordination
good news for a region that
>> Sudden severe headache
sits at the northern end of the
with no known cause
so-called “stroke belt,” a swath
of mostly southern states
stretching west to Texas with
a high incidence of stroke. “The treatments that we now
have,” says Leon-Guerrero, “have been proven to lower the
amount of damage people suffer from strokes.” The evolution of advances in stroke treatment can be described in
three categories:
>> Primary stroke prevention: Preventive measures, such
as diet, blood pressure control, and exercise, can lower
the risk of stroke.
>> Acute treatment: IV tPA (intravenous tissue plasminogen activator) clot-busting medication can be given in
the first 4 1/2 hours to dissolve the clot and results in
better clinical outcomes for patients.
>> Endovascular procedures: These are designed to restore perfusion to the brain in areas that are blocked off.
For example, a stent-retriever or “stent-triever,” can be
used to deploy a stent to pull the clot out of an artery.
“We offer this to patients up to six hours from symptom onset,” says Leon-Guerrero. “The clot has to be in
a blood vessel that’s reachable by catheter, a proximal
large vessel occlusion. Some clots are so small that they
are not amenable to this procedure.”

“This designation demonstrates not only the unique expertise of our
physicians, but also the exacting collaborative procedures that GW Hospital
has developed involving everyone from the transport staff, technologists,
nurses, and physicians to the CEO and hospital leadership.”
HENRY KAMINSKI, M.D.

Leon-Guerrero says elapsed time is of the essence. “The
earlier you treat, the more likely the patient will benefit,”
he says. “These devices are also all time dependent.” Disagreement among practitioners remains over treating patients beyond the six hour mark. Another contentious issue
is figuring out when to start the clock when a person wakes
up with stroke symptoms. As of yet, no biomarkers in the
blood have been discovered that could put a “time stamp”
on onset.
Damage to the core of the brain is inevitable in virtually
all strokes. The part of the brain not getting enough
blood, but which is salvageable, is the penumbra (the cells surrounding a blockage
where blood flow and oxygen levels
are reduced). “The sooner we can
restore profusion, the more of the
penumbra we can save,” LeonGuerrero explains.
When a person suffers a
stroke, the treatment protocol
shifts to secondary stroke prevention, aimed at reducing the
risk of reoccurrence. GW Hospital has a 16-bed inpatient
rehabilitation unit. “We use an
evaluation system called the
Functional Independent Measure,
an ordinal scale from one to seven
that determines the level of assistance
the patient needs,” says Annu Sharma,
D.O., instructor of neurology, who works
in the rehab department at GW Hospital. The

LIMITING THE DAMAGE
Damage to the core of the brain is inevitable in virtually all strokes. The part of the brain not getting enough
blood, but which is salvageable, is the penumbra. The
sooner profusion is restored, the more of the penumbra can be saved. The benefits of aggressive therapy are
substantial and relatively rapid. Recovery can be seen
in three to four weeks, sometimes in two weeks.

evaluation covers amACT FAST
bulation, transportation,
F ace: Facial drooping
mobility, and self-care,
A rm: Arm weakness
and it is scaled from total
independence to maxiS peech: Difficulty or slurred speech
mum assistance needed.
T ime: Call 911 immediately
Following the CSC
certification, the unit has
been receiving more referrals from stroke. Along with Ty Lai, M.D., instructor of
neurology at SMHS, Sharma manages the unit and
they determine, with the neurologist, how
much daily therapy can be tolerated. “We
have to be alert to changes in cognition during evaluation; whether a
stroke might be getting bigger, or
a new stroke is occurring,” she
adds.
The benefits of aggressive
therapy are substantial and relatively rapid. “We can see recovery in three to four weeks,
sometimes in two weeks,” she
says. “We see patients go from
being significantly weak on
one side to being able to have
fully restored function.”
Among the basic requirements
for a CSC is to treat 20 or more patients per year with a diagnosis of subarachnoid hemorrhage caused by an aneurysm and to administer IV tPA 25 or more times
per year for eligible patients with acute ischemic stroke.
Leon-Guerrero says GW Hospital is expecting 600 to
700 stroke patients in 2016 and welcomes the new status
the hospital has for serving the community. “I enjoy acute
decision-making,” he explains. “I like to deal with patients
who are faced with these unfortunate life-changing events,
and neurology is filled with life-changing events. There’s a
chance you can make a huge and lasting impact on someone’s life.”
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Addressing Global Mental Health Issues
Across Town and Around the World
GLOBAL MENTAL HEALTH PROGRAM PROVIDES UNIQUE TRAINING OPPORTUNITIES FOR RESIDENTS
BY THOMAS KOHOUT AND SANDEEP RAVINDRAN
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Since 2011, according to the United Nations High Commissioner for Refugees,
4.8 million men, women, and children have fled Syria, a nation devastated by five
years of warfare. Nearly 7 million more are internally displaced within the country.
Many of those fleeing the destruction take an arduous route out of Syria, traveling hundreds of miles on foot across Turkey to the Aegean Sea. From the Turkish coast, the refugees board overcrowded boats for a risky water-crossing to reach Greek islands Chios
and Lesbos, and then it’s on to the Greek mainland and into Europe. Along the way, teams
of nongovernmental organization (NGO) aid workers triage the incoming refugees, spotting the sick from among the weary and offering what help they can. Amidst the flow of
refugees, volunteers, global media, and border patrols during a peak in the exodus last
November 2015 stood Catherine May, M.D., associate clinical professor of psychiatry and
behavioral sciences at the GW School of Medicine and Health Sciences (SMHS), assessing the mental health landscape on behalf of medical NGO Remote Area Medical (RAM).
It was an emergency mission made possible by Allen Dyer, M.D., Ph.D., professor of
psychiatry and behavioral sciences at SMHS, who leads the department’s Global Mental Health residency track program. RAM was organizing a medical response mission to
Greece, which is serving as a primary stop-over location for Syrian refugees. The group
turned to Dyer for a recommendation based on previous associations as well as his reputation as a global mental health expert. He assembled a team led by May that included
GW resident alumni Nicole Nguyen Perras, M.D., RESD ’16, and Sandeep Denduluri, M.D.,
RESD ’14. May’s mission was organized in fairly short order, in part because the department’s second-year residents were already engaged in a simulation exercise where they
were preparing to respond to a yet-to-occur global disaster.
At the height of the refugee influx, Greece was receiving as many as 6,000 refugees a
day. They were in “migration” mode, eager to reach northern Europe, focused on physical, not emotional, needs.
“That situation rapidly changed in March 2016, with the European Union-Turkey accord,” explains Dyer. “With refugees unable to move forward, local resources became
strained and the humanitarian workers soon became overwhelmed.”
The United States Embassy in Athens, in conjunction with Greek NGO METAdrasi, again
turned to Dyer and May to lead a program, “Building Resilience in Humanitarian Workers,”
which took place in Athens in June 2016. The program also provided an opportunity for
Fatima Noorani, M.D., RESD ’16, who participated in the workshop while still a resident.

Specializing in Global Mental Health

PRIORITIZING MENTAL HEALTH CARE
Whether health care professionals
are working in a post-conflict setting,
in low-income countries with limited
resources, or with refugees and torture
survivors in the United States, mental
health is a crucial aspect of care.
Often underfunded, mental health
care is vital to a long, healthy life.

The department has been involved with Global Mental Health for nearly two decades.
Five years ago, James Griffith, M.D., chair of the Department of Psychiatry and Behavioral Sciences and Leon M. Yochelson Professor of Psychiatry at SMHS, parlayed the department’s clinical expertise into the nationally recognized Global Mental Health (GMH)
residency training program. While all of GW’s psychiatry residents participate in GMH
training, and second-year residents participate in a variety of seminar series, typically a
quarter of GW’s 24 residents seek more specialized training.
As the head of the GMH program, Dyer prepares psychiatry residents to respond. Residents in the GMH track participate in up to a year’s worth of international training experiences, while fourth-year residents can spend as much as eight months of their final year
of training on international missions. During the past two years, GMH track residents participated in projects in Bangalore, India; West Bank, Palestine; Nigeria; Cambodia; Natal,
South Africa; and Greece.
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These projects serve as unique learning opportunities,
says Griffith. “Most of the time, you’re working with a very
high-need population that has very few resources, little
funding, and very few mental health professionals,” he explains, “so there’s a lot of improvisation, learning how to use
the strengths of a culture, strengths of families, to promote
mental health.”
In the early years of the program, residents bore their
costs of travel for international projects, while GW maintained continued salary
support. Fortunately, the
Charles and Sonia Akman
Professorship in Global
Psychiatry, established in
2012, now offsets the travel expenses for many of
those international projects. Together with travel
funds from the Department of Psychiatry and
Behavioral Sciences and
the SMHS Office of International Medicine Programs, personal expenses
for residents on international rotations have been
substantially reduced.

Around the world,

mental health is the

number one priority
in terms of Disease

Adjusted Life

Years, the measure
of the impact of

health problems.

Global Mental Health Begins at Home
Around the world, mental health is the number one priority in terms of Disease Adjusted Life Years, the measure of
the impact of health problems. Whether health care professionals are working in a post-conflict setting, in low-income
countries with limited resources, or with refugees and torture survivors in the United States, mental health is a crucial aspect of care. “These are all different populations of
people, but they share in common abusive circumstances
or settings where there are very few resources for mental
health,” says Griffith.
To that end, the department’s GMH track has become an
important feature of the school’s residency program. “This
is a big drawing card, and one of the reasons that residents
come across the country to train here rather than somewhere else,” he says. In recognition of its innovative curriculum, the American College of Psychiatrists awarded the
global mental health program the 2016 Award for Creativity
in Psychiatric Education.
The program was a good fit for the multi-ethnic Washington, D.C. area, which, according to Griffith, is estimated to have more than 40,000 political torture-survivors in
addition to other refugees from more than 50 countries.
Residents in the GMH track rotate at the Northern Virginia Family Service, which provides community mental
health services to immigrant and refugee populations.
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It’s “a perfect example of the global mental health work that
we do locally,” says Eindra Khin Khin, M.D., RESD ’08, B.S.
’01, assistant professor of psychiatry and behavioral sciences at SMHS.
Khin Khin leads the department’s Human Rights Clinic,
which works in close collaboration with Physicians for Human Rights to assess asylum seekers. Most individuals have
suffered political oppression and have been tortured by
their governments or “under color of the law” in their home
countries. Their asylum petitions are based upon the threat
of harm were they to return to their home countries. Others seek asylum protection as victims of human trafficking or
other crimes under the Victims of Trafficking and Violence
Protection Act.
“In this day and age of globalization, you really don’t have
to leave wherever you are to do global mental health projects,” says Khin Khin, who has worked with many immigrant
and refugee populations, and supervises pro bono psychiatric evaluations for people seeking asylum status in the
United States.
She isn’t alone in her commitment to global mental health.
For Michael D. Morse, M.D., RESD ’16, clinical instructor
of psychiatry and behavioral sciences at SMHS, practicing
medicine — specifically the diagnosis and treatment of patients with mental disorders — was always part of his plan. It
wasn’t until he journeyed to Jerusalem between college and
medical school, however, that he witnessed how his passion
for psychiatry and global health could have a real impact on
physicians and patients in the Middle East.
“With courage, humility, and dogged persistence, Michael has opened doors in the West Bank and Gaza, and
showed how building mental health services can further the
cause of peace,” says Griffith.
In 2008, Morse, while still a student at the Harvard Medical School, created the Palestinian Medical Education Initiative (PMED), an international NGO based in the West Bank
and in the United States. By 2015, the group earned international recognition, receiving funding from the German
Regional Fund for the Middle East and North Africa to integrate mental health services into primary care settings in
Gaza and the West Bank, and for parenting classes and other
mental health initiatives in Ramallah.
“Cross-cultural competency is an essential part of any
residency training,” says Amir Afkhami, M.D. ’03, Ph.D., associate professor of psychiatry and behavioral sciences, and
of global health at SMHS, highlighting a strength of GW’s
program. “Integrating global mental health in that training is
a great vehicle to teach that to residents.”
He adds that “there’s much to learn from the global health
setting in terms of engaging with the community, and it’s
more important than ever. Most places don’t have the kind
of faculty that we have at George Washington University,
with the kind of experience that we have, where this can be
taught in the way we can.”

The Refugee Mind
CROSS-CULTURAL AWARENESS AND SUICIDE PREVENTION
BY LAURA OTTO

“How can we improve suicide prevention services for refugees in the United States,
as well as create feasible solutions in settings within the United States where refugees
are commonly resettled but there is almost no psychiatric care?” asked Brandon
Kohrt, M.D., Ph.D., RESD ’13, assistant professor of psychiatry, global health, and
cultural anthropology at the Duke Global Health Institute at Duke University.

PREVENTING SUICIDE IN REFUGEES
In his presentation, “Suicide Prevention: Cross-Cultural Perspectives for
Refugees and Global Mental Health,”
Brandon Kohrt, M.D., Ph.D., RESD ’13,
assistant professor of psychiatry,
global health, and cultural anthrology at Duke University, addressed
how people think about suicide
from a global perspective and how
that can inform how we better treat
refugees in the United States.
Disaster, war, conflict; trauma and
abuse; discrimination; stresses of
acculturation and dislocations; and
isolation and lack of social support are
all important risk factors for suicide.

Kohrt returned to the GW School of Medicine and Health Sciences (SMHS) to deliver the
22nd Annual Seymour Perlin, M.D., Lecture on Suicidology. Perlin, Professor Emeritus of
Psychiatry and Behavioral Sciences at SMHS, led the school’s psychiatry residency program from 1977 to 1993. The Seymour Perlin, M.D., endowment fund was established
in 1987 to honor the renowned leader and mentor
who specialized in the field of suicidology and to
support an annual grand rounds lecture series focusing on suicide.
In his presentation, “Suicide Prevention: CrossCultural Perspectives for Refugees and Global
Mental Health,” Kohrt addressed how people think
about suicide from a global perspective and how
that can inform how we better treat refugees in the
United States.
“The United States is the largest recipient of
Bhutanese refugees, about 800,000 have settled
here,” says Kohrt. “If you look at refugees in the
United States, Bhutanese have a suicide rate of
24.4 per 100,000. This is a higher suicide rate than
when the Bhutanese were living in refugee camps
in Nepal, or for Bhutanese resettled in other countries.”
Disaster, war, conflict; trauma and abuse; discrimination; stresses of acculturation and
dislocations; and isolation and lack of social support are all important risk factors, according to Kohrt, and part of refugees’ experiences, making them a highly vulnerable group.
However, refugee resettlement policies in the United States often resettle refugees in
rural areas where mental health services are difficult to access. They also separate members of extended families that had lived together for decades in refugee camps, sending
them to different regions of the United States where they can no longer maintain their
connectedness.
“The take-home message here is the concept of ethnopsychology, the idea that every
cultural group has their own way of understanding emotions, feeling, senses, suffering,”
he says. There are two key pieces to this for the Bhutanese refugees. “One is the idea of
the heart-mind, the location of emotions and memories; the other is the idea of the brainmind, where logic and social control and expectations are all modulated.”
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